Exploratory subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase III study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC).
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Martin Reck, Luis G. Paz-Ares, Paolo Bidoli, Federico Cappuzzo, Shaker R. Dakhil, Denis Moro-Sibilot, Hossein Borghaei, Melissa Lynne Johnson, Robert M. Jotte, Nathan A. Pennell, Frances A. Shepherd, Anne S. Tsao, Gebra Cuyun Carter, Faye Diehl, Ekaterine Alexandris, Pablo Lee, Annamaria Zimmermann, Joseph Treat, Andreas Sashegyi, Maurice Perol
Institutions: German Center for Lung Research, LungenClinic Grosshansdorf, Hospital Universitario Virgen del Rocío, Azienda Ospedaliera San Gerardo, Ospedale di Livorno, Cancer Center of Kansas, Hôpital Albert Michallon, Fox Chase Cancer Center, Sarah Cannon, Rocky Mountain Cancer Centers, Cleveland Clinic, Princess Margaret Cancer Centre, The University of Texas MD Anderson Cancer Center, Eli Lilly (United States), Centre Léon Bérard
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2464815665